What is it about?
Brucellosis is a zoonotic systemic infectious disease caused by Brucella abortus. Antibiotics remain the mainstay of treatment, but the urgent need for new drug molecules to combat this disease is driven by the emergence of antibiotic resistance. This paper reviews the research progress of small molecule antimicrobial inhibitors developed against different targets of Brucella.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This review is the first to provide a comprehensive summary of the progress of research on small molecule inhibitors of Brucella abortus, including almost all research work prior to the publication of this paper. The aim is to facilitate a more rapid understanding of this area and to save researchers' time.
Perspectives
This is the inaugural review of my graduate school career. In the process of writing it, I gained considerable knowledge and developed several research ideas. It is my hope that this article will prove useful to researchers in this field, as well as inspiring to researchers in other fields.
Yingnan Wu
Read the Original
This page is a summary of: Small Molecule Inhibitors against the Bacterial Pathogen Brucella, Current Medicinal Chemistry, August 2024, Bentham Science Publishers,
DOI: 10.2174/0929867331666230915153910.
You can read the full text:
Contributors
The following have contributed to this page
